1. Introduction and Background
MK-677, also designated L-163,191 and known by the generic name ibutamoren mesylate, is a synthetic non-peptide compound that stimulates growth hormone (GH) secretion through agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a). First reported by (Patchett et al., 1995), MK-677 was developed at Merck Research Laboratories through a medicinal chemistry programme that sought to translate the GH-releasing activity of peptide-based secretagogues into a small molecule with oral bioavailability. This goal represented a significant departure from the prevailing approach to GH secretagogue development, which had relied on synthetic peptides such as GHRP-6, GHRP-2, and hexarelin that required parenteral administration due to rapid proteolytic degradation and poor gastrointestinal absorption.
The pharmacological rationale for MK-677 was grounded in the observation that the GHS-R1a receptor, cloned by (Howard et al., 1996) from porcine and human pituitary tissue, accepted structurally diverse ligands. This receptor promiscuity suggested that non-peptide scaffolds could be engineered to achieve receptor activation with acceptable potency and selectivity. The subsequent identification of ghrelin as the endogenous GHS-R1a ligand by (Kojima et al., 1999) confirmed that MK-677 functioned as a ghrelin mimetic, operating through the same receptor system that mediates the physiological regulation of pulsatile GH release, appetite signalling, and energy homeostasis.
This review examines the published literature on the pharmacology, clinical pharmacokinetics, and research applications of MK-677, with emphasis on its effects on the GH/IGF-1 axis, body composition, sleep physiology, and bone metabolism. The compound is discussed in the context of its unique position as the most extensively studied orally active ghrelin receptor agonist, and current research directions are considered.
2. Mechanism of Action: Ghrelin Receptor Agonism
MK-677 exerts its primary pharmacological effect through high-affinity binding to GHS-R1a, the seven-transmembrane G-protein-coupled receptor that constitutes the principal mediator of ghrelin signalling in the somatotroph axis (Howard et al., 1996). Upon binding, MK-677 activates the Gq/11 signalling cascade, stimulating phospholipase C to hydrolyse phosphatidylinositol 4,5-bisphosphate into inositol trisphosphate (IP3) and diacylglycerol. The resulting IP3-mediated release of calcium from the endoplasmic reticulum, together with subsequent calcium influx through voltage-gated channels, elevates intracellular calcium concentrations in anterior pituitary somatotrophs, triggering GH vesicle exocytosis (Smith, 2005).
Importantly, this signalling mechanism is functionally complementary to, rather than redundant with, the pathway engaged by growth hormone releasing hormone (GHRH). GHRH signals through the GHRH receptor via Gs-coupled adenylate cyclase activation and cyclic AMP production, such that concurrent stimulation by both GHRH and a GHS-R1a agonist produces a synergistic GH response that exceeds the sum of individual effects. This synergy has been consistently observed in both animal models and human studies, and accounts in part for the substantial GH elevations reported with MK-677 administration, as the compound amplifies endogenous GHRH-driven pulsatile secretion rather than overriding the hypothalamic-pituitary regulatory framework (Copinschi et al., 1996).
Unlike peptide secretagogues, the non-peptide structure of MK-677 confers resistance to enzymatic degradation by gastrointestinal and plasma proteases, enabling absorption through the intestinal epithelium and effective oral dosing. The spiroindanylpiperidine scaffold identified by (Patchett et al., 1995) achieves GHS-R1a binding through hydrophobic and hydrogen-bonding interactions that differ structurally from the peptide backbone contacts used by ghrelin and synthetic GHRPs, yet produce equivalent receptor activation as measured by intracellular calcium mobilisation assays. This structural dissimilarity has implications for receptor kinetics and desensitisation behaviour, as the binding orientation and residency time of small-molecule agonists may differ from those of peptide ligands (Holst and Schwartz, 2004).
3. Pharmacokinetics and Oral Bioavailability
The defining pharmacokinetic characteristic of MK-677 is its oral bioavailability, a property that distinguishes it from virtually all other GH secretagogues that have reached clinical investigation. Following oral administration in human subjects, MK-677 is rapidly absorbed, with peak plasma concentrations typically achieved within one to two hours. The compound exhibits a terminal elimination half-life of approximately six to eight hours, though its biological effects on GH pulsatility and IGF-1 elevation persist substantially beyond this window, consistent with a pharmacodynamic duration that outlasts the pharmacokinetic half-life (Copinschi et al., 1996).
In early dose-ranging studies conducted in young healthy male volunteers, single oral doses of MK-677 ranging from 5 to 25 mg produced dose-dependent increases in serum GH, with maximal secretory responses observed at the 25 mg dose level. Repeated daily dosing at 25 mg for seven days was shown to increase 24-hour integrated GH concentrations by approximately 97%, while raising IGF-1 levels by approximately 40% from baseline (Copinschi et al., 1996). Notably, these GH elevations were achieved while preserving the pulsatile pattern of GH secretion, with increases observed in both pulse amplitude and the interpulse nadir, suggesting augmentation rather than disruption of the normal neuroendocrine rhythm.
The oral route of administration has practical implications for chronic dosing protocols. (Chapman et al., 1996) demonstrated that daily oral administration of MK-677 at 25 mg over 28 days in healthy elderly subjects produced sustained elevations in IGF-1 concentrations to levels characteristic of healthy young adults, without tachyphylaxis or progressive attenuation of the GH secretory response. This absence of desensitisation over the study period was noteworthy, as it contrasted with the declining GH responses sometimes observed with continuous exogenous GHRH or GH-releasing peptide infusions, and may reflect the intermittent pharmacokinetic profile of once-daily oral dosing.
4. Clinical Research: GH/IGF-1 Axis and Body Composition
The most extensively characterised clinical effect of MK-677 is its capacity to elevate circulating GH and IGF-1 concentrations in both young and elderly populations. (Chapman et al., 1996) reported that four weeks of daily oral MK-677 administration to healthy subjects aged 64 to 81 years increased mean 24-hour GH concentrations and restored serum IGF-1 levels to the range observed in younger individuals. This finding was of particular interest because the age-related decline in GH secretion, termed somatopause, is associated with changes in body composition, bone density, and functional capacity, and the question of whether restoring youthful GH/IGF-1 concentrations through secretagogue-based approaches could attenuate these changes became a central line of investigation.
The two-year randomised controlled trial conducted by (Nass et al., 2008) represents the longest published clinical study of MK-677. In this trial, 65 healthy older adults (60-81 years) received daily oral MK-677 at 25 mg or placebo for up to two years. MK-677 treatment produced sustained increases in GH and IGF-1 concentrations throughout the study period, confirming the absence of long-term tachyphylaxis. With respect to body composition, MK-677-treated subjects exhibited increases in fat-free mass and decreases in visceral adiposity as measured by dual-energy X-ray absorptiometry, though body weight also increased modestly, attributed in part to fluid retention and appetite-stimulating effects mediated through GHS-R1a activation in hypothalamic feeding centres.
In a distinct clinical context, (Murphy et al., 1998) investigated MK-677 in a caloric restriction model, demonstrating that seven days of oral MK-677 administration at 25 mg reversed nitrogen wasting induced by dietary caloric restriction in healthy volunteers. Nitrogen balance, an indirect marker of protein catabolism, improved significantly compared with placebo, suggesting that the GH and IGF-1 elevations produced by MK-677 were sufficient to exert protein-sparing effects under catabolic conditions. This observation has informed ongoing research interest in the potential utility of ghrelin receptor agonists in states characterised by accelerated muscle protein degradation.
5. Effects on Sleep Architecture
A notable area of MK-677 research concerns its effects on sleep physiology. The relationship between GH secretion and sleep is well established: the largest daily GH pulse in humans occurs during slow-wave sleep (SWS), and manipulations that enhance GH release have been associated with alterations in sleep architecture. In the seven-day trial by (Copinschi et al., 1996), polysomnographic recordings in healthy young men receiving MK-677 revealed a significant increase in the duration of stage IV sleep and in the total amount of REM sleep, the latter increasing by approximately 50% relative to baseline. These effects were accompanied by a reduction in the frequency of sleep interruptions.
The mechanism by which MK-677 modulates sleep architecture is not fully elucidated but is hypothesised to involve both the direct effects of enhanced GH secretion on central sleep-regulating circuits and the broader neuromodulatory activity of ghrelin receptor signalling in hypothalamic nuclei involved in circadian regulation. GHS-R1a expression has been identified in brain regions outside the pituitary-hypothalamic somatotroph axis, including areas implicated in sleep-wake cycling, suggesting that MK-677 may engage central pathways that influence sleep independently of its peripheral GH-releasing activity (Holst and Schwartz, 2004). These findings have attracted research interest regarding the broader neurobiological significance of ghrelin receptor agonism beyond the somatotroph axis.
6. Bone Metabolism
The GH/IGF-1 axis plays a well-characterised role in bone physiology, with both GH and IGF-1 stimulating osteoblast proliferation and activity, and IGF-1 serving as a paracrine mediator of GH effects on bone formation. The capacity of MK-677 to sustain GH and IGF-1 elevations has prompted investigation of its effects on markers of bone metabolism. (Murphy et al., 1999) examined the effects of MK-677 in healthy elderly adults and in functionally impaired elderly subjects residing in long-term care facilities. In both populations, MK-677 administration increased serum osteocalcin, a marker of osteoblast activity, and urinary cross-linked N-telopeptides of type I collagen, a resorption marker, consistent with an overall increase in bone turnover.
The interpretation of increased bone turnover in this context requires nuance. An initial phase of coupled bone formation and resorption is a recognised pharmacological response to agents that stimulate the GH/IGF-1 axis, and longitudinal assessment is required to determine whether net bone formation exceeds resorption over extended treatment periods. In the two-year trial by (Nass et al., 2008), the pattern of bone marker changes was consistent with an early remodelling transient followed by stabilisation, though the study was not powered to detect changes in fracture incidence or bone mineral density as primary endpoints. These observations remain an active area of investigation in age-related musculoskeletal research.
7. Safety Observations in Clinical Studies
Across published clinical trials, the most consistently reported effects of MK-677 include mild, transient increases in appetite, modest increases in body weight, and transient oedema attributed to fluid retention. In the two-year study by (Nass et al., 2008), fasting glucose concentrations were modestly elevated in the MK-677 group relative to placebo, an observation consistent with the known counter-regulatory effects of GH on insulin sensitivity. These metabolic observations are of particular relevance for the design of chronic dosing protocols in populations with pre-existing insulin resistance and underscore the importance of glycaemic monitoring in extended research applications involving GH secretagogues.
Cortisol concentrations were also examined in multiple studies. (Copinschi et al., 1996) reported a modest and transient increase in morning cortisol levels during the first days of MK-677 treatment that normalised with continued administration, suggesting an initial hypothalamic-pituitary-adrenal axis perturbation that undergoes adaptation. Prolactin and thyroid hormone levels remained within reference ranges across studies, consistent with the relative selectivity of MK-677 for the GHS-R1a pathway over other pituitary secretory axes (Chapman et al., 1996).
8. Current Research Directions
Contemporary research interest in MK-677 extends across several domains. The compound continues to serve as a pharmacological tool for investigating the physiology of ghrelin receptor signalling, as its oral bioavailability and well-characterised pharmacokinetic profile enable chronic dosing studies that would be logistically impractical with injectable peptide secretagogues (Smith, 2005). In the field of ageing research, the capacity of MK-677 to restore youthful GH/IGF-1 profiles without requiring exogenous GH administration has sustained interest in secretagogue-based approaches to somatopause, particularly as the long-term safety and efficacy data from the (Nass et al., 2008) trial provide a foundation for larger and more targeted investigations.
Research into the catabolic reversal properties of MK-677, first demonstrated by (Murphy et al., 1998), continues to inform the broader field of sarcopenia and cachexia research. The protein-sparing effects observed under caloric restriction conditions have prompted preclinical and translational investigations into whether ghrelin receptor agonism can attenuate muscle wasting in disease states characterised by accelerated proteolysis. Additionally, the sleep-modulating effects identified by (Copinschi et al., 1996) have opened a research avenue at the intersection of endocrinology and sleep medicine, where the relationship between ghrelin receptor activity, slow-wave sleep, and nocturnal GH secretion is being examined in greater mechanistic detail.
Finally, the bone turnover data reported by (Murphy et al., 1999) have prompted interest in longer-duration studies designed to assess whether sustained GHS-R1a agonism produces measurable changes in bone mineral density or fracture risk in elderly populations. As the global research community continues to explore the therapeutic potential of the GH/IGF-1 axis in age-related decline, MK-677 occupies a distinctive position as the only non-peptide, orally bioavailable ghrelin receptor agonist with an extensive published clinical evidence base.